Prandin, GlucoNorm, NovoNorm, Repaglinide | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Prandin, GlucoNorm, NovoNorm, Repaglinide
Health Canada Patents

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

Contact Supplier

IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

Contact Supplier

medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

Contact Supplier

Coral

Contact Supplier

ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

Contact Supplier

Prandin, GlucoNorm, NovoNorm, Repaglinide

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

29 API Suppliers, 12 USDMF, 11 CEP/COS, 3 JDMF, 8 EU WC, 2 KDMF, 6 NDC API, 18 Listed Suppliers, $ API Reference Price

29 API Suppliers
12 USDMF
11 CEP/COS
3 JDMF
8 EU WC
2 KDMF
6 NDC API
18 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

40 Drugs in Development

40 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

329 FDF Dossiers, 31 FDA Orange Book, 252 Europe, 15 Canada, 6 South Africa, 25 Listed Dossiers

329 FDF Dossiers
31 FDA Orange Book
252 Europe
15 Canada
6 South Africa
25 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 500MG;1MG, TABLET;ORAL - 500MG;2MG

TABLET;ORAL - 0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 500MG;1MG
TABLET;ORAL - 500MG;2MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Rochem International Inc, 6 SPI Pharma, 3 DKSH, 4 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 1 Kirsch Pharma, 5 Actylis, 1 Aeon Procare, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 27 BASF, 1 Corel Pharma Chem, 3 DFE Pharma, 1 Doshion Polyscience, 2 Esteem Industries, 2 Finar, 9 Gangwal Chemicals, 1 Ideal Cures, 3 Ingredion Pharma Solutions, 1 Kerry, 2 Keval Exports, 8 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 6 Pluviaendo, 3 Prachin Chemical, 25 Roquette, 1 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 Silverline Chemicals, 1 Ulanqab Kema New Material, 2 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

47 Fillers, Diluents & Binders, 22 Direct Compression, 20 Disintegrants & Superdisintegrants, 20 Granulation, 20 Solubilizers, 20 Thickeners and Stabilizers, 17 Topical, 16 Film Formers & Plasticizers, 16 Lubricants & Glidants, 15 Taste Masking, 13 Coating Systems & Additives, 13 Co-Processed Excipients, 12 Controlled & Modified Release, 11 Parenteral, 9 Chewable & Orodispersible Aids, 6 Emulsifying Agents, 2 API Stability Enhancers, 2 Surfactant & Foaming Agents, 2 Coloring Agents, 2 Rheology Modifiers, 1 Soft Gelatin

47 Fillers, Diluents & Binders
22 Direct Compression
20 Disintegrants & Superdisintegrants
20 Granulation
20 Solubilizers
20 Thickeners and Stabilizers
17 Topical
16 Film Formers & Plasticizers
16 Lubricants & Glidants
15 Taste Masking
13 Coating Systems & Additives
13 Co-Processed Excipients
12 Controlled & Modified Release
11 Parenteral
9 Chewable & Orodispersible Aids
6 Emulsifying Agents
2 API Stability Enhancers
2 Surfactant & Foaming Agents
2 Coloring Agents
2 Rheology Modifiers
1 Soft Gelatin

DIGITAL CONTENT

8 News #PharmaBuzz

8 News #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 99 Regulatory FDF Prices, 5 Annual Reports

4 US Medicaid Prescriptions
99 Regulatory FDF Prices
5 Annual Reports

MARKET PLACE

7 APIs, 2 FDF Dossiers

7 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 Health Canada Patents

3 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 6 Others

3 EDQM
6 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 2,464 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

3 All

01 3Novo Nordisk Canada Inc.

filter Patent Reset all filters

3 All

01 32111851

filter Product Reset all filters

3 All

01 3Repaglinide

filter Dosage Reset all filters

3 All

01 3Tablet

filter Exp Date Reset all filters

3 All

01 32011-06-21

Product Main Page

01

Novo Nordisk Canada Inc.

Repaglinide

OPRD

Not Confirmed

Novo Nordisk Canada Inc.

OPRD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Repaglinide

Brand Name : GLUCONORM

Patent Number : 2111851

Filing Date : 1991-06-21

Strength per Unit : 0.5mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Novo Nordisk Canada Inc.

Repaglinide

OPRD

Not Confirmed

Novo Nordisk Canada Inc.

OPRD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Repaglinide

Brand Name : GLUCONORM

Patent Number : 2111851

Filing Date : 1991-06-21

Strength per Unit : 1.0mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Novo Nordisk Canada Inc.

Repaglinide

OPRD

Not Confirmed

Novo Nordisk Canada Inc.

OPRD

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Repaglinide

Brand Name : GLUCONORM

Patent Number : 2111851

Filing Date : 1991-06-21

Strength per Unit : 2.0mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2011-06-21

Date Granted : 2002-02-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!